NS
Roles
Therapeutic Areas
REMD Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| REMD-477 (Volagidemab) | Type 1 Diabetes | Phase 3 (planned) |
| REMD-477 (Volagidemab) + GLP-1 | Obesity / Type 2 Diabetes | Phase 2 (planned) |
| BC008-1A (Bispecific) | Not specified (Oncology/Immunology) | Phase 1 |